Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yimofeng Biotechnology

Request full access

Advanced CAR-T cell therapies for solid tumors

Suzhou Shi, ChinaFounded 2020Biotech & Life Sciences

About Yimofeng Biotechnology

Yimofeng Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation Chimeric Antigen Receptor (CAR) T-cell immunotherapies for the treatment of cancer. The company is particularly concentrated on addressing the challenges associated with treating solid tumors.

The core of Yimofeng's research involves reprogramming a patient's own T-cells to recognize and attack cancer cells. A key area of their work includes developing strategies to overcome the immunosuppressive tumor microenvironment, which often limits the effectiveness of CAR-T therapies in solid tumors. One novel approach involves an inverted cytokine receptor (ICR) designed to block inhibitory signals like TGF-β within the tumor and convert them into stimulative signals for the CAR-T cells, enhancing their persistence and function.

The company has a pipeline of candidates, including treatments for metastatic colorectal cancer (mCRC) and prostate cancer. Its lead program, GCC19CART, has shown promising clinical activity in treating relapsed/refractory mCRC in trials conducted in both China and the United States, with the potential to be a first-in-class CAR-T product for this type of cancer. Yimofeng operates as an integrated international biotechnology firm with a proprietary CoupledCAR™ platform, designed to enhance the in-vivo expansion and efficacy of CAR-T cells against metastatic solid tumors.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Suzhou Shi, China
Open positions
None listed
Dealroom signal
18.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2022 $28M $110M Guosheng Capital · SDIC Venture Capital ↗
SPINOUT✓Other financing Jul 2020 $0 — Fudan University · Shanghai Jiao Tong University —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yimofeng Biotechnology in the Suzhou Shi ecosystem

Live from Dealroom

The Yimofeng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Guosheng Capital
  • SDIC Venture Capital

Other known investors2 additional known investors

  • Fudan University
  • Shanghai Jiao Tong University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yimofeng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yimofeng Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.